Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

B. Tran; F. Meric-Bernstam; H. T. Arkenau; R. Bahleda; R. K. Kelley; C. Hierro; D. Ahn; A. Zhu; M. Javle; R. Winkler; H. He; J. Huang; L. Goyal

doi:10.1093/annonc/mdy432.007

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

B. Tran, F. Meric-Bernstam, H. T. Arkenau, R. Bahleda, R. K. Kelley, C. Hierro, D. Ahn, A. Zhu, M. Javle, R. Winkler, H. He, J. Huang, L. Goyal

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	ix49-ix50
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy432.007
State	Published - Nov 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy432.007

Cite this

Tran, B., Meric-Bernstam, F., Arkenau, H. T., Bahleda, R., Kelley, R. K., Hierro, C., Ahn, D., Zhu, A., Javle, M., Winkler, R., He, H., Huang, J., & Goyal, L. (2018). Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's. Annals of oncology : official journal of the European Society for Medical Oncology, 29, ix49-ix50. https://doi.org/10.1093/annonc/mdy432.007

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's. / Tran, B.; Meric-Bernstam, F.; Arkenau, H. T. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.11.2018, p. ix49-ix50.

Research output: Contribution to journal › Article › peer-review

Tran, B, Meric-Bernstam, F, Arkenau, HT, Bahleda, R, Kelley, RK, Hierro, C, Ahn, D, Zhu, A, Javle, M, Winkler, R, He, H, Huang, J & Goyal, L 2018, 'Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. ix49-ix50. https://doi.org/10.1093/annonc/mdy432.007

Tran B, Meric-Bernstam F, Arkenau HT, Bahleda R, Kelley RK, Hierro C et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29:ix49-ix50. doi: 10.1093/annonc/mdy432.007

Tran, B. ; Meric-Bernstam, F. ; Arkenau, H. T. et al. / Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. ix49-ix50.

@article{bc86e30576dc45e3984a8c4319da572f,

title = "Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's",

author = "B. Tran and F. Meric-Bernstam and Arkenau, {H. T.} and R. Bahleda and Kelley, {R. K.} and C. Hierro and D. Ahn and A. Zhu and M. Javle and R. Winkler and H. He and J. Huang and L. Goyal",

year = "2018",

month = nov,

day = "1",

doi = "10.1093/annonc/mdy432.007",

language = "English (US)",

volume = "29",

pages = "ix49--ix50",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

AU - Tran, B.

AU - Meric-Bernstam, F.

AU - Arkenau, H. T.

AU - Bahleda, R.

AU - Kelley, R. K.

AU - Hierro, C.

AU - Ahn, D.

AU - Zhu, A.

AU - Javle, M.

AU - Winkler, R.

AU - He, H.

AU - Huang, J.

AU - Goyal, L.

PY - 2018/11/1

Y1 - 2018/11/1

UR - http://www.scopus.com/inward/record.url?scp=85074696267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074696267&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy432.007

DO - 10.1093/annonc/mdy432.007

M3 - Article

C2 - 32178046

SN - 0923-7534

VL - 29

SP - ix49-ix50

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this